Breyanzi car t-transplant
Ended Awarded Last action
- Contract number
- 36C24926F0137
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 9
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $364,139
Award facts
- Contract value 100% obligated
- $364,139.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lawrenceville, Lawrence Township, NJ 08648, USA
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 9 (VISN 9), awarded a $364,139.25 firm fixed-price delivery order to Bristol-Myers Squibb Company for the supply of BREYANZI (lisocabtagene maraleucel), a chimeric antigen receptor T-cell therapy used to treat non-Hodgkin lymphoma. Awarded on May 29, 2026 with an ultimate completion date of August 31, 2026, this delivery order carries no set-aside designation and will be performed at Bristol-Myers Squibb's facility in Lawrenceville, New Jersey. The award represents a single task order issued under Bristol-Myers Squibb's Federal Supply Schedule contract (ID: 36F79724D0101) for Pharmaceuticals and Drugs (FSS-61-IB), a General Services Administration master schedule vehicle with a substantial ceiling value of $12.3 billion extending through April 30, 2029.
Bristol-Myers Squibb, a global biopharmaceutical manufacturer specializing in oncology, immunotherapy, and specialized cell therapies, serves as a critical supplier of advanced cancer treatments to the Department of Veterans Affairs. The company has received more than fifty documented delivery orders since 2022 across multiple Veterans Integrated Service Networks, with the majority supporting VISN 9's mission to provide state-of-the-art oncology and immunotherapy treatments to eligible veterans. This delivery order for BREYANZI continues the company's sustained engagement in supplying CAR T-cell therapies and specialty oncology pharmaceuticals that represent the current standard of care in advanced cancer treatment within the VA healthcare system.
Quick answers
Who was awarded contract 36C24926F0137?
36C24926F0137 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 9 (Veterans Health Administration) on May 29, 2026.
How much is contract 36C24926F0137 worth?
The government has obligated $364,139 on 36C24926F0137.
Is contract 36C24926F0137 an order under another contract?
Yes. 36C24926F0137 is a delivery order under 36F79724D0101, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24926F0137 competed?
The extent of competition for 36C24926F0137 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award